tiprankstipranks
Advertisement
Advertisement

HK:2696 Stock Latest News

Henlius Wins NMPA Nod to Begin Trials of HER2 Breast Cancer Biosimilar HLX319
Company AnnouncementsHenlius Wins NMPA Nod to Begin Trials of HER2 Breast Cancer Biosimilar HLX319
7d ago
2696
Henlius Wins NMPA Nod to Start Trials of Novel Hyaluronidase Injection
PremiumCompany Announcements
Henlius Wins NMPA Nod to Start Trials of Novel Hyaluronidase Injection
8d ago
2696
Henlius Wins Key EMA Backing for Cancer Drug Serplulimab in Europe
PremiumCompany Announcements
Henlius Wins Key EMA Backing for Cancer Drug Serplulimab in Europe
9d ago
2696
Henlius Starts Phase 1b/2 Trial of CD47-Targeting HLX701 in Advanced Colorectal Cancer
PremiumCompany Announcements
Henlius Starts Phase 1b/2 Trial of CD47-Targeting HLX701 in Advanced Colorectal Cancer
14d ago
2696
Henlius Wins NMPA Nod for Phase 1 Trial of Nivolumab Biosimilar HLX18
PremiumCompany Announcements
Henlius Wins NMPA Nod for Phase 1 Trial of Nivolumab Biosimilar HLX18
19d ago
2696
Henlius Boosts 2025 Revenue as Global Drug Approvals Broaden Its Biologic Portfolio
PremiumCompany AnnouncementsHenlius Boosts 2025 Revenue as Global Drug Approvals Broaden Its Biologic Portfolio
19d ago
2696
Henlius Taps Fosun Affiliate to Promote HANBEITAI in Connected-Party Deal
Premium
Company Announcements
Henlius Taps Fosun Affiliate to Promote HANBEITAI in Connected-Party Deal
19d ago
2696
Shanghai Henlius revamps Hong Kong company secretary and governance roles
Premium
Company Announcements
Shanghai Henlius revamps Hong Kong company secretary and governance roles
19d ago
2696
Henlius Wins NMPA Nod for Novel Lung Cancer Combination Trial
PremiumCompany Announcements
Henlius Wins NMPA Nod for Novel Lung Cancer Combination Trial
23d ago
2696
Henlius Wins NMPA Nod to Launch First-in-Class HLX316 Cancer Trial
PremiumCompany Announcements
Henlius Wins NMPA Nod to Launch First-in-Class HLX316 Cancer Trial
1M ago
2696
Henlius Wins NMPA Clearance to Begin Trials of First-in-Class Tetra-Specific Cancer Antibody HLX3901
PremiumCompany Announcements
Henlius Wins NMPA Clearance to Begin Trials of First-in-Class Tetra-Specific Cancer Antibody HLX3901
1M ago
2696
Henlius Wins NMPA Clearance to Begin First-in-Human Trial of Novel KAT6 Inhibitor HLX97
PremiumCompany Announcements
Henlius Wins NMPA Clearance to Begin First-in-Human Trial of Novel KAT6 Inhibitor HLX97
1M ago
2696
Shanghai Henlius Biotech Sets March Board Meeting to Approve 2025 Results
PremiumCompany AnnouncementsShanghai Henlius Biotech Sets March Board Meeting to Approve 2025 Results
1M ago
2696
Henlius Starts Phase 2/3 Trial of HLX22-HLX87 Combo in HER2-Positive Metastatic Breast Cancer
Premium
Company Announcements
Henlius Starts Phase 2/3 Trial of HLX22-HLX87 Combo in HER2-Positive Metastatic Breast Cancer
1M ago
2696
Henlius Wins Key EMA Backing for Pertuzumab Biosimilar HLX11 in Europe
Premium
Company Announcements
Henlius Wins Key EMA Backing for Pertuzumab Biosimilar HLX11 in Europe
1M ago
2696
Henlius Reshapes Global Licensing Strategy for HANSIZHUANG With Abbott and KGBio
PremiumCompany Announcements
Henlius Reshapes Global Licensing Strategy for HANSIZHUANG With Abbott and KGBio
1M ago
2696
Henlius Wins U.S. FDA IND Nod for Multiple Myeloma Biosimilar HLX15-SC
PremiumCompany Announcements
Henlius Wins U.S. FDA IND Nod for Multiple Myeloma Biosimilar HLX15-SC
2M ago
2696
Henlius Wins NMPA Nod to Start Trials of Daratumumab Biosimilar HLX15-SC
PremiumCompany Announcements
Henlius Wins NMPA Nod to Start Trials of Daratumumab Biosimilar HLX15-SC
2M ago
2696
Henlius Starts Phase 1b/2 Trial of HLX43 Combinations in Advanced Colorectal Cancer
PremiumCompany Announcements
Henlius Starts Phase 1b/2 Trial of HLX43 Combinations in Advanced Colorectal Cancer
2M ago
2696
Henlius Grants Eisai Japan Rights to Flagship Cancer Drug HANSIZHUANG in Lucrative Licensing Deal
PremiumCompany AnnouncementsHenlius Grants Eisai Japan Rights to Flagship Cancer Drug HANSIZHUANG in Lucrative Licensing Deal
2M ago
2696
Shanghai Henlius Completes Full Circulation of H Shares on Hong Kong Stock Exchange
Premium
Company Announcements
Shanghai Henlius Completes Full Circulation of H Shares on Hong Kong Stock Exchange
2M ago
2696
Henlius Wins NMPA Nod for Triple-Drug Cancer Combination Trial Centered on HLX43
Premium
Company Announcements
Henlius Wins NMPA Nod for Triple-Drug Cancer Combination Trial Centered on HLX43
2M ago
2696

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >